Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vortioxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 20/20 | 1.00 |
| ▸ | HTR3A known ✓ | P46098 | 20/20 | 1.00 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 6/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 6/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 2/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 2/20 | 1.00 |
| ▸ | HRH2 | P25021 | 2/20 | 1.00 |
| ▸ | HTR1B | P28222 | 2/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | HTR2C | P28335 | 2/20 | 1.00 |
| ▸ | HTR7 | P34969 | 2/20 | 1.00 |
| ▸ | HRH1 | P35367 | 2/20 | 1.00 |
| ▸ | HTR5A | P47898 | 2/20 | 1.00 |
| ▸ | HTR6 | P50406 | 2/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.97 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vortioxetine SCHEMBL29402460 | 1.00 | HTR1A (1.00) | HTR1AHTR3ACYP1A2CYP3A4CYP2D6 | |
| Vortioxetine SCHEMBL29469584 | 0.99 | HTR1A (1.00) | HTR1AHTR3ACYP1A2CYP3A4CYP2D6 | |
| Vortioxetine SCHEMBL15623040 | 0.99 | HTR1A (1.00) | HTR1AHTR3ACYP1A2CYP3A4CYP2D6 | |
| Vortioxetine SCHEMBL236115 | 0.99 | HTR1A (1.00) | HTR1AHTR3ACYP1A2CYP3A4CYP2D6 | |
| Vortioxetine SCHEMBL19717678 | 0.97 | HTR1A (0.97) | HTR1AHTR3ACYP1A2CYP3A4CYP2D6 | |
| Vortioxetine SCHEMBL29393393 | 0.97 | HTR1A (0.97) | HTR1AHTR3ACYP1A2CYP3A4CYP2D6 | |
| Vortioxetine SCHEMBL18687167 | 0.97 | HTR1A (0.97) | HTR1AHTR3ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL29633102 | 0.97 | HTR1A (0.97) | HTR1AHTR3ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL28470746 | 0.97 | HTR1A (0.97) | HTR1AHTR3ACYP1A2CYP3A4CYP2D6 | |
| Vortioxetine SCHEMBL237653 | 0.97 | HTR1A (0.97) | HTR1AHTR3ACYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160083359-A1 | 1-[2-(2,4-DIMETHYLPHENYLSULFANYL)-PHENYL]PIPERAZINE AS A COMPOUND With COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT | LUNDBECK & CO AS H (DK) | 2016-03-24 | — | — | US | claimed |
| US-20240101524-A1 | A METHOD FOR PREPARATION OF 1-(2-((2,4-DIMETHYLPHENYL)THIO)PHENYL) PIPERAZINE AND ITS SALTS | R L FINE CHEM PRIVATE LIMITED (IN) | 2024-03-28 | — | — | US | disclosed |
| EP-4247802-A1 | A METHOD FOR PREPARATION OF 1-(2-((2,4-DIMETHYLPHENYL)THIO)PHENYL) PIPERAZINE AND ITS SALTS | R L Fine Chem Private Limited (IN) | 2023-09-27 | — | — | EP | disclosed |
| US-20230021520-A1 | 1-[2-(2,4-DIMETHYLPHENYLSULFANYL)-PHENYL]PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT | H. LUNDBECK A/S (DK) | 2023-01-26 | — | — | US | disclosed |
| WO-2022254248-A1 | A METHOD FOR PREPARATION OF 1-(2-((2,4-DIMETHYLPHENYL)THIO)PHENYL) PIPERAZINE AND ITS SALTS | R L FINE CHEM PRIVATE LIMITED (IN) | 2022-12-08 | — | — | WO | disclosed |
| US-11458134-B2 | 1-[2-(2,4-dimeihylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment | H. LUNDBECK A/S (DK) | 2022-10-04 | — | — | US | disclosed |
| US-20210087155-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF VORTIOXETINE AND SALTS THEREOF | Piramal Enterprises Limited (IN) | 2021-03-25 | — | — | US | disclosed |
| US-20210087155-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF VORTIOXETINE AND SALTS THEREOF | Piramal Enterprises Limited (IN) | 2021-03-25 | — | — | US | disclosed |
| EP-2044043-B2 | 1- Ý[- (2, 4-DIMETHYLPHENYLSULFANYL) -PHENYL]PIPERAZINE HYDROBROMIDE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT | H LUNDBECK AS (DK) | 2021-03-03 | — | — | EP | disclosed |
| EP-3762371-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF VORTIOXETINE AND SALTS THEREOF | Piramal Enterprises Limited (IN) | 2021-01-13 | — | — | EP | disclosed |
| US-8664225-B2 | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of pain or residual symptoms in depression relating to sleep and cognition | H. LUNDBECK A/S (DK) | 2014-03-04 | — | — | US | disclosed |
| EP-2439201-B1 | COMPOUNDS WITH COMBINED SERT, 5-HT3 AND 5-HT1A ACTIVITY | LUNDBECK & CO AS H (DK) | 2013-08-07 | — | — | EP | disclosed |
| EP-2044043-B1 | 1- Ý[- (2, 4-DIMETHYLPHENYLSULFANYL) -PHENYL]PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT | LUNDBECK & CO AS H (DK) | 2012-01-11 | — | — | EP | disclosed |
| EP-2142193-B1 | 1-[2-(2,4-DIMETHYLPHENYLSULFANYL)PHENYL]PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF PAIN OR RESIDUAL SYMPTOMS IN DEPRESSION RELATING TO SLEEP AND COGNITION | LUNDBECK & CO AS H (DK) | 2011-01-19 | — | — | EP | disclosed |
| US-20110009422-A1 | 1- [2-(2,4-DIMETHYLPHENYLSULFANYL)-PHENYL] PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF PAIN OR RESIDUAL SYMPTOMS IN DEPRESSION RELATING TO SLEEP AND COGNITION | H LUNDBECK A/S (DK) | 2011-01-13 | — | — | US | disclosed |
| US-20100297240-A1 | 1- [2- (2,4-DIMETHYLPHENYLSULFANYL)-PHENYL] PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT | H. LUNDBECK A/S (DK) | 2010-11-25 | — | — | US | disclosed |
| EP-2142193-A2 | 1-[2-(2,4-DIMETHYLPHENYLSULFANYL)PHENYL]PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF PAIN OR RESIDUAL SYMPTOMS IN DEPRESSION RELATING TO SLEEP AND COGNITION | H.Lundbeck A/S (DK) | 2010-01-13 | — | — | EP | disclosed |
| EP-2044043-A1 | 1- Ý[- (2, 4-DIMETHYLPHENYLSULFANYL) -PHENYL]PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT | H.Lundbeck A/S (DK) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008113359-A2 | 1- [2-(2,4-DIMETHYLPHENYLSULFANYL)-PHENYL] PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF PAIN OR RESIDUAL SYMPTOMS IN DEPRESSION RELATING TO SLEEP AND COGNITION | H. LUNDBECK A/S (DK) | 2008-09-25 | — | — | WO | disclosed |
| WO-2007144005-A1 | 1- [2- (2, 4-DIMETHYLPHENYLSULFANYL) -PHENYL] PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT | H. LUNDBECK A/S (DK) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297240-A1 | 1- [2- (2,4-DIMETHYLPHENYLSULFANYL)-PHENYL] PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT | HTR3A, HTR2C, HTR5A | HTR1A 5/4885HTR3A 1/4885SLC6A4 20/4885 |
| US-20240101524-A1 | A METHOD FOR PREPARATION OF 1-(2-((2,4-DIMETHYLPHENYL)THIO)PHENYL) PIPERAZINE AND ITS SALTS | TPMT, HTR2A, HTR2C | HTR1A 25/4885HTR3A 84/4885SLC6A4 356/4885 |
| US-11458134-B2 | 1-[2-(2,4-dimeihylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment | HTR3A, HTR2C, HTR2A | HTR1A 5/4885HTR3A 1/4885SLC6A4 20/4885 |
| US-20110009422-A1 | 1- [2-(2,4-DIMETHYLPHENYLSULFANYL)-PHENYL] PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF PAIN OR RESIDUAL SYMPTOMS IN DEPRESSION RELATING TO SLEEP AND COGNITION | HTR2C, HTR3A, HTR2A | HTR1A 5/4885HTR3A 2/4885SLC6A4 21/4885 |
| US-20160083359-A1 | 1-[2-(2,4-DIMETHYLPHENYLSULFANYL)-PHENYL]PIPERAZINE AS A COMPOUND With COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT | HTR3A, HTR2C, HTR5A | HTR1A 5/4885HTR3A 1/4885SLC6A4 20/4885 |
| US-20210087155-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF VORTIOXETINE AND SALTS THEREOF | HTR5A, CYP3A5, CYP4B1 | HTR1A 17/4885HTR3A 28/4885SLC6A4 6/4885 |
| US-20230021520-A1 | 1-[2-(2,4-DIMETHYLPHENYLSULFANYL)-PHENYL]PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT | HTR3A, HTR2C, HTR5A | HTR1A 5/4885HTR3A 1/4885SLC6A4 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.